With the improvement of the R&D strength of domestic innovative pharmaceutical enterprises and the intensification of the "involution" of the domestic pharmaceutical market, going global will become one of the important layouts for the sustainable development of
local pharmaceutical companies.
Among them, Germany is one of the three major axis countries in Europe and has sound laws and regulations, creating better business opportunities and conditions
for overseas investors.
Since the beginning of this year, many local pharmaceutical companies have accelerated their layout in Germany, taking advantage of Germany's central position in Europe to expand the entire European market
.
Recently, some media reported that Chime (Wuhan) Biopharmaceutical Co.
, Ltd.
has established a European business center in Germany and is actively expanding the European biomedical market
.
It is reported that the establishment of the European business center is an important step
in Chime Biologics' globalization strategy.
The establishment of this European business center means that Chime Biologics will move into overseas markets, and will further broaden its channels, accelerate the layout of global territory, and empower global partners
in the future.
According to the data, Chime Biologics is a large CDMO company headquartered in Wuhan, Hubei Province, adhering to customer-centric, timely, economical and high-quality service-oriented
.
The company provides a one-stop, integrated solution that supports early-stage drug development through late-stage clinical research and commercial cGMP manufacturing to meet the dynamic needs
of the rapidly evolving biopharmaceutical industry.
The company is committed to improving human health
by manufacturing innovations that make biopharmaceuticals of international standards affordable to all patients worldwide, raising the level of treatment.
Earlier, in March, Biocytogen (Beijing) Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Biocytogen") announced the establishment and official operation
of the Biocytogen European Innovation Center (BEIC) in Heidelberg, Germany.
It is reported that Biocytogen set up the European Innovation Center in Heidelberg, which is a very important step
in the company's globalization strategy.
The company expects to leverage the local innovation environment, facilities and talent resources to deepen cooperation with European partners in the development of new target drugs and clinical drug development of "Thousand Mouse Antibodies", and advance the company's vision
of becoming a global new drug originator.
According to the data, Biocytogen is a domestic biopharmaceutical company committed to innovative technology-driven new drug research and development, committed to becoming the global birthplace of new drugs, with the mission
of focusing on technological innovation, continuous new drug production, and protecting human health.
Based on the fully human antibody RenMice platform (RenMab and RenLite mice) independently developed by Biocytogen and has completely independent intellectual property rights, the monoclonal antibody and biclonal antibody development technology platform, animal in vivo efficacy screening platform and strong clinical development capabilities are organically integrated to form a unique new drug research and development capability
covering the whole process of drug research and development.
The company is conducting large-scale drug development on more than 1,000 potentially druggable targets ("Thousand Mouse AntibodiesTM" program), has signed 17 drug co-development agreements and entered into RenMice platform licensing cooperation
with 14 companies, including several MNCs.
The company has established a pipeline of 12 core drug products, of which 2 products are in phase II of international multi-center (MRCT) clinical trials and 2 are in phase
I clinical trials.
Biocytogen has continued to produce many drug candidate molecules with FIC and BIC potential, and will continue to work with global partners to produce many FIC and BIC antibody drugs to better benefit patients
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
